Last mentioned: Mar 25, 2026
Charles Schwab reported record-breaking 2025 results with $12 trillion in client assets and a 50% surge in adjusted EPS, signaling a powerful recovery in the brokerage sector. Conversely, life sciences firm MaxCyte is navigating a 15% revenue decline as cell therapy customers consolidate programs and reduce capital expenditures.
MaxCyte reported a 15% revenue decline for 2025, driven by the loss of six clinical programs and reduced spending from its largest customer. Despite these headwinds, the company improved gross margins to 78% and expanded its installed base to 857 instruments, signaling long-term platform persistence.
MaxCyte reported a 15% revenue decline for 2025, driven by the loss of six clinical programs and reduced spending from its largest customer. Despite these headwinds, the company expanded its installed base to 857 units and significantly improved gross margins through aggressive cost-cutting measures.